** Analysts at Morningstar raise fair value estimate on Australia's Polynovo Ltd PNV.AX by 5% to A$1.15
** Medical devices maker Polynovo, on Tuesday, recorded its highest ever monthly sales of A$10.1 mln ($6.3 mln) in November
** Company logged total group revenue of A$49.6 mln till November, up 25.5% vs the same period last year
** Fiscal 2025 revenue forecast of A$136 mln ($84.95 mln) implies 32% growth on last year as we anticipate a stronger-second half on favourable currency movements and continued market share gains - Morningstar
** Six of eight analysts rate the stock "buy" or higher, two "hold"; their median PT is A$2.77, according to data compiled by LSEG
** PNV stock down 24.5% YTD, as of the last close
($1 = 1.6010 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。